Open Access News

News from the open access movement

Thursday, September 13, 2007

More on Elevier's OncologySTAT

Barbara Fister at ACRLog:

So, let me get this straight: Having big pharma fund access is okay, but public funding is not because it might corrupt the peer review process. Huh?

Julian Fisher on LibLicense:

While Elsevier is taking its bows, we at Scholarly Exchange have had that model for our wide array of journals for the past two years. It helps reduce the total annual running cost of $750 per journal per year to somewhat less - and for journals in the proper fields, may turn them into - heaven forbid - profit centers!